Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

91.21USD
15 Dec 2017
Change (% chg)

$6.73 (+7.97%)
Prev Close
$84.48
Open
$91.06
Day's High
$92.07
Day's Low
$90.17
Volume
322,304
Avg. Vol
43,268
52-wk High
$104.09
52-wk Low
$59.67

Summary

Name Age Since Current Position

Rajesh Parekh

48 2004 Non-Executive Chairman of the Board

Onno van de Stolpe

58 1999 Chief Executive Officer, Executive Director, Member of the Executive Committee

Bart Filius

2017 Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer

Piet Wigerinck

2012 Member of the Executive Committee, Chief Scientific Officer

Elizabeth Goodwin

VP Corporate Communications & Investor Relations

Walid Abi-Saab

2017 Member of the Executive Committee, Chief Medical Officer

Andre Hoekema

Member of the Executive Committee, Chief Business Officer

Harrold van Barlingen

52 2005 Non-Executive Director

Katrine Bosley

2013 Independent Non-Executive Director

Werner Cautreels

65 2009 Non-Executive Independent Director

Mary Kerr

Non-Executive Independent Director

Christine Mummery

2015 Non-Executive Independent Director

Howard Rowe

2010 Non-Executive Independent Director

Biographies

Name Description

Rajesh Parekh

Dr. Rajesh Parekh has been Non-Executive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company's Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2005. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc.; Avila Therapeutics, Inc.; EUSA Pharma (Europe) Limited; Thiakis Limited; and Amsterdam Molecular Therapeutics (AMT) Holding N.V. (now uniQure). Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners; Advent Life Sciences LLP; Aleta Inc.; Arrakis, Inc.; Aura Inc.; Artax Inc.; Capella BioSciences Ltd.; Cellnovo Limited; EnCipher Limited; Itara Limited; Levicept Limited; Macrolide Pharmaceuticals, Inc.; PE Limited; and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4-Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor.

Onno van de Stolpe

Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Member of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene (now Crucell). Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V. Mr. Onno van de Stolpe received a Master of Science degree from the Agricultural University in Wageningen.

Bart Filius

Mr. Bart Filius has served as Chief Financial Officer of Galapagos NV since December 1, 2014. He has over 13 years’ experience at Sanofi. Since September 2017 he also has occupied the post of the Company's Member of the Executive Committee, Chief Operating Officer. During the past three years as CFO Sanofi Europe, Bart was instrumental in transforming the Sanofi European organization to be well positioned beyond the patent cliff. Earlier at Sanofi, Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Bart led and completed the divestiture of various franchises. Prior to joining Sanofi, he was a strategy consultant at Arthur D. Little. Mr. Bart Filius has an MBA degree from INSEAD and a bachelor’s degree in business from Nyenrode University.

Piet Wigerinck

Dr. Piet Wigerinck has served as Member of the Executive Committee, Chief Scientific Officer of Galapagos NV since April 18, 2012. He was Senior Vice President - Development from April 1, 2008. Dr. Wigerinck joined the Company in April 2008 from Tibotec (a subsidiary of Johnson & Johnson) where he was Vice President of Drug Discovery, Early Development and CM&C, and Member of the Management Board. He started his professional career as medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) was selected and moved forward into clinical trials. He brings over 15 years of research and development experience from both big pharmaceuticals and biotech to Galapagos. Dr. Wigerinck holds a Doctorate in Philosophy from the Catholic University of Louvain and is inventor on more than 25 patent applications.

Elizabeth Goodwin

Walid Abi-Saab

Mr. Walid Abi-Saab has been Member of the Executive Committee, Chief Medical Officer of Galapagos NV since March 2017. He drives the overall medical strategy of the Company and is responsible for late stage clinical development and operations, medical and regulatory affairs, and safety. Before, hebworked at Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, he was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program. Mr. Walid Abi-Saab holds an MD degree from Universite Saint Joseph in Beirut, Lebanon.

Andre Hoekema

Dr. Andre Hoekema is Member of the Executive Committee, Chief Business Officer at Galapagos NV. He joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe. Dr. Hoekema currently also serves as a Member of the Supervisory Board of Mimetas B.V. He has 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and MOGEN (Research and Project Management) and Genentech, Inc. Dr. Hoekema has a Doctorate in Philosophy degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States.

Harrold van Barlingen

Dr. Harrold van Barlingen has been Non-Executive Director of Galapagos NV since 2005. He is Member of the Audit Committee of the Company. He is Managing Director and Founder of Thuja Capital. Prior to founding Thuja Capital, he headed the life science effort of AlpInvest Partners. Previously, he was at the Boston Consulting Group, where he worked as a Consultant in management and strategy. Prior to BCG, Dr. van Barlingen headed the Benelux office of the Lewin Group (a Quintiles subsidiary); an international firm specialized in the field of health economy. He currently serves on the Supervisory Boards of Encare Biotech B.V., TheraSolve NV, Indigo Diabetes NV (chairman) and Hemics B.V. (chairman). In addition, during the last five years he also served on the boards of Okapi Sciences NV, and arGEN-X N.V. Dr. Harrold van Barlingen holds a MSc in Medical Biology and a Doctorate in Philosophy in the area of cardiovascular diseases, both from the University of Utrecht.

Katrine Bosley

Ms. Katrine Bosley has been Independent Non-Executive Director of Galapagos NV since February 27, 2013. She is Member of the Remuneration and Nominating Committee. She has served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. since June 2014. Prior to joining Editas, she was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012, she was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. She served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners, Inc. Ms. Bosley graduated from Cornell University with a B.A. in Biology. She currently serves as chairman of the board of Genocea Biosciences, Inc. and as a director of Scholar Rock, LLC. She also serves on the board of directors of the Biotechnology Innovation Organization and is a review committee member of the Wellcome Trust.

Werner Cautreels

Dr. Werner Cautreels has been Non-Executive Independent Director of Galapagos NV since June 2, 2009. He is Member of the Company's Nomination and Remuneration Committee and Chairman of the Company's Audit Committee. He is President and Chief Executive Officer (CEO) of Selecta Biosciences. Previously, Dr. Cautreels was Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in February 2010. Prior to joining Solvay he was employed by Sanofi, Sterling Winthrop and Nycomed Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a Director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, United States) from 1999 to 2006. He was President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. Dr. Werner Cautreels graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He also holds a Bachelors degree and Master of Science in Chemistry from the University of Antwerp. He received his management and financial education from the Harvard Business School.

Mary Kerr

Dr. Mary Kerr is Non-Executive Independent Director of Galapagos NV. She is Chief Executive Officer and Director at NeRRe Therapeutics. Prior to her appointment at NeRRe, Mary held a range of senior leadership roles at GSK over more than 20 years, most recently as Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. Mary was a founding member and on the Corporate Executive team of ViiV Healthcare where she led a turnaround in the performance of the HIV business in Europe. She has spent the majority of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Dr. Mary Kerr gained a Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit and has an MBA from the University of Kingston.

Christine Mummery

Dr. Christine Mummery has been appointed as Non-Executive Independent Director effective as of Galapagos NV since November 4, 2015. As of 2008, Dr. Christine Mummery is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre (LUMC) in The Netherlands. After her PhD in BioPhysics at London University, she was postdoctoral fellow at the Hubrecht Institute in Utrecht, later also staff member and group leader. She became Professor at the Interuniversity Cardiology of the Netherlands (ICIN) at the University Medical Centre Utrecht in 2002. In 2007, she was a joint Harvard Stem Cell Institute/Radcliffe fellow at Harvard and Massachusetts General Hospital at the time human induced pluripotent stem cells were being developed and was the first to derive iPSC lines from patients. Her primary research focus is currently the development and use of stem cells in cardiovascular development and disease. She served on the Ethical Councils of the Ministry of Health, is member of the Royal Netherlands Academy of Arts and Sciences (KNAW), editor in chief/editorial board member of several journals, former board member of ISSCR and past-president of the International Society of Differentiation. In addition, she is on the board of ZonMW (Dutch Medical Research Council) and chairs the executive board of the hDMT Institute for human Organ and Disease Model technologies, a non-profit R&D institute of which Galapagos is a founding partner.

Howard Rowe

Dr. Howard Rowe has been Non-Executive Independent Director of Galapagos NV since August 5, 2010. He is also Member of the Audit Committee. He was previously Managing Director with Goldman Sachs where he had multiple Healthcare responsibilities over his 12 years at the firm. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. During that time he served on the boards of EUSA Pharma, Healthcare Brands International, MedAvante, SmallBone Innovations and Ikonisys. Prior to his investing activities, Dr. Rowe was Senior Member of the European Healthcare Investment Banking team, where he advised numerous corporate clients on Mergers & Acquisitions and corporate finance activities. Before joining Goldman Sachs, he was Corporate Lawyer with the law firm Sullivan & Cromwell. In the past, Mr. Rowe has served as a member of the board of directors of MedAvante, Inc. Dr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California, and his Juris Doctor from Harvard Law School.